$BWET

ETF fueled by Iran war goes bonkers, gains 3,600%

Breakwave Tanker Shipping ETF (BWET) surged 3,600% this year, reaching $726 per share. The gain is attributed to the U.S.-Iran war, which disrupted oil shipping through the Strait of Hormuz, increasing tanker hiring rates. Analysts expect prolonged Middle East conflict to sustain pressure on shipping routes.

Original reporting
Published Sep 18, 2026, 9:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 10:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ETF fueled by Iran war goes bonkers, gains 3,600% — source image
Decision brief

The 30-second read

$BWETBullishLow
01

Why it matters

The ETF’s explosive YTD gain underscores the sensitivity of freight‑linked assets to geopolitical shocks.

02

Market read

BWET’s surge signals heightened risk in oil logistics; traders may watch related shipping stocks and freight futures.

03

What to watch

Potential for alternative routes to stabilize and for new tanker capacity to enter the market, easing rates.

Relevance 4/10Novelty 3/10Timing: current YTD performance

Background

The article explains how the Iran‑U.S. war and Houthi activity have constrained the Strait of Hormuz, inflating tanker hiring rates and driving BWET’s performance.

Company-level read

Ticker impact

$BWETBullishMedium confidence
Context

Breakwave Tanker Shipping ETF (BWET) has risen about 3,600% YTD as Iran‑U.S. conflict restricts oil flows through the Strait of Hormuz.

Expected impact

Further upside possible if shipping disruptions persist; downside risk if conflict eases.

Evidence & confidence

ETF tracks short‑dated freight futures; current geopolitical shock drives rates, but the rally may be near a peak after a 3600% run.

Market effects

Elevated freight rates benefit shipping and logistics stocks, while raising oil transport costs.

Middle East shipping disruptions increase risk premiums for energy markets.

Highlights geopolitical risk to global oil supply chain and related ETFs.

Counterpoint

The ETF may be overbought after a massive run; a de‑escalation could trigger a sharp correction.

Key entities

  • Breakwave Tanker Shipping ETF

    Tracks short‑dated oil‑tanker freight futures.

  • John Kartsonas

    Founder and managing partner of Breakwave Advisors.

Related articles

$MUMed

A Shipping ETF No One Has Heard Of Has Quietly Run 700%, Tripling Micron’s Rally V1

Breakwave Tanker Shipping ETF (BWET) rose from $19.26 on Dec. 31, 2025 to $160.22 by May 26, 2026, a 731.68% year-to-date gain, according to Fuse’s adjusted price series. The article attributes the move to near-dated crude oil tanker freight futures tied to VLCC rates after U.S.-Iran tensions disrupted Strait of Hormuz insurance, pushing Middle East-to-Asia hauling costs to record levels. It contrasts this with Micron’s 214.04% rally over the same period.

$BWETMedAI 8/10

The Breakwave Tanker ETF Just Posted a 1,406% Return. Here’s What Actually Happened.

Amplify Commodity Trust’s tanker shipping ETF (BWET) rose about 1,406% over one year, from $10.55 on May 29, 2025 to $158.86 a year later, according to the article. It attributes the move to the February 2026 closure of the Strait of Hormuz, which lengthened tanker routes and tightened VLCC freight capacity. The article also cites a 725% year-to-date gain through May 29, 2026.

$CAVAHigh

Why is CAVA stock surging today?

CAVA stock rose 5.5% to $55.40 after opening its first Wisconsin restaurant, its 31st U.S. state. Analysts from Bank of America and KeyBanc reiterated Buy ratings with targets of $107 and $80. Q3 2026 earnings are due November 4. The rally was driven by company-specific news, not broader market trends.

$TWSTMed

Why is Twist Bioscience stock surging today?

Twist Bioscience (TWST) stock rose 8.9% after launching Twist Express Screening Antibodies, a service for rapid antibody production. The company's ties to AI-driven drug discovery and positive analyst sentiment contributed to the surge, with shares reaching an intraday high of $174.87. The broader market had minimal impact on the stock's movement.

$GMABHighAI 9/10

Why is Genmab stock surging today?

Genmab's stock rose 16.8% after its Phase 3 LiGeR-HN1 trial showed a 50% reduction in death risk for a combination treatment. Analysts upgraded the stock, with JPMorgan raising its price target to DKK 3,500 and TD Cowen to $52.00. The trial results were well-received, with no new safety concerns.